CSL Limited
CSL.AXDividend Aristocrat • 25yrsAutomated dividend-safety read-out from payout, leverage, yield, profitability and track record. See the Financials tab for the full per-statement Financial Investigation. Educational only — not investment advice.
At a glance
CSL Limited (CSL.AX) operates in the Biotechnology industry and is based in Australia. It pays a twice-yearly dividend of A$4.05 a year, a yield of 2.03% at the current price of A$197.29. CSL has raised its dividend for 25 consecutive years, which makes it a Dividend Aristocrat. Over the last five years the dividend has grown by an average of 9.0% a year. It paid out 45% of its earnings as dividends, leaving most of its profit in the business. 16 analysts cover it; their average 12-month price target of A$201.03 is 1.9% above the current price.
Written automatically from the figures on this page, as of Nov 19, 2026. Facts only, not a recommendation.
About CSL Limited
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants.
Business description from Yahoo Finance. Verify details in the company's own annual report.
Key Metrics
Valuation
Profitability
Financial Health
Data provided by Yahoo Finance via yfinance. Updated daily. Not investment advice.